查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2125254

注射式藥物輸送裝置：市場洞察、競爭格局及市場預測 - 2034年

Injectable Drug Delivery Devices - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

概述：

  • 2025年注射藥物輸送裝置的市場規模估計為442億美元，預計到2034年將達到914億美元。該成長是由以下因素推動的：生物製藥和GLP-1療法的自我給藥方式的加速普及、家庭慢性病管理的快速發展，以及對預充式注射器、自動注射器和聯網注射筆平台的大規模生產投資。
  • 全球注射式藥物輸送裝置市場預計在2026年至2034年的預測期內將以 8.4%的CAGR成長。
  • 依產品類型分類，到2025年，胰島素筆市場佔有率達到 41%，推動注射給藥裝置市場的發展。
  • 依藥物填充方法，到2025年，預填充填充裝置細分市場以 59%的佔有率主導注射藥物輸送裝置市場。
  • 依可重複使用性角度，到2025年，拋棄式設備細分市場將主導注射藥物輸送設備市場，佔 64%。
  • 依給藥部位，到2025年，皮下給藥部分將佔市場佔有率的68%，引領注射給藥裝置市場。
  • 依最終用戶分類，到2025年，居家照護環境細分市場佔45%的市場佔有率，引領注射藥物輸送設備市場。
  • 到2025年，北美以 39%的市場佔有率引領全球注射藥物輸送設備市場，成為全球市場佔有率最高的地區。

注射給藥裝置是醫療設備，目的是透過肌肉、皮內或皮下途徑將藥物和生物製藥直接輸送到體內，包括自動注射器、無針注射器、穿戴式注射器和胰島素筆。隨著生物製藥、生物相似藥、GLP-1受體促效劑和單株抗體等藥物開發平臺的快速擴展，對精準且病患友善的腸外給藥的需求日益成長。製藥公司擴大與專業的醫療設備製造商和組件供應商合作，開發藥物和醫療設備的組合產品，而不是依賴傳統的管瓶和注射器系統。這些供應商提供預填充和可重複填充的裝置平台、可重複使用和拋棄式使用的產品，以及整合的連接功能，以支援劑量準確性、用藥依從性追蹤以及在臨床環境之外的安全自我給藥。市場依產品類型細分為自動注射器、無針注射器、穿戴式注射器和胰島素筆。此外，就藥物填充形式而言，注射裝置可分為預填充型和可重複填充型；就可重複使用性而言，可分為可重複使用型和拋棄式型；就給藥部位而言，可分為肌肉注射、皮內預填充式注射器和皮下注射。另外，就最終用戶而言，醫院和專科診所最為常見，而居家照護則是主要關注點。隨著自我給藥生物製藥和GLP-1療法的興起、對複方製劑產品監管支持的加速推進，以及對預填充注射器和自動注射器生產能力的持續資本投入，注射給藥裝置已成為將慢性病和專科生物製藥療法從診所轉移到家庭護理的重要基礎設施。

注射式藥物輸送裝置市場的主要成長促進因素

  • 自我給藥生物製藥和 GLP-1 受體促效劑療法的快速臨床和商業性擴張推動需求，預計到2030年，全球接受 GLP-1 療法的患者人數將超過 8,000萬人。
  • 隨著全球糖尿病負擔加重，對胰島素筆和連網給藥系統的需求不斷成長，國際糖尿病聯盟（IDF）預測，到2030年，全球糖尿病患者人數將超過 6.43億。
  • 製藥和生物技術公司正日益將慢性病和特殊生物製劑療法轉移到家庭給藥，推動了對用戶最佳化型自動注射器、筆式注射器和穿戴式注射器平台的需求。
  • 監管支援的加速，包括 FDA 於2024年發布的最新複合產品指南，加速醫療設備和藥品的共同開發，並增加對醫療設備商業化生產的需求。
  • 對預填充式注射器和自動注射器生產能力的重大資本投資，例如 BD 在內布拉斯加州投資 1.1億美元進行擴建，以及Ypsomed投資約 5億瑞士法郎增加產能，日益擴大醫療設備的供應網路。
  • 對人為因素、複雜產品和品質系統的嚴格要求，推動了對具有良好監管合規記錄和檢驗的平台的醫療設備製造商的需求。
  • 受生物製藥的成長、慢性病負擔的加重、居家照護的擴張以及製造業投資的推動，預計到2034年，該市場將保持高個位數的強勁成長。

推動注射式藥物輸送裝置市場成長的因素

市場促進因素

自我給藥生物製藥和GLP-1療法的快速發展

注射給藥裝置市場最強勁的驅動力是自動給藥生物製藥和GLP-1受體促效劑療法的臨床和商業性快速成長。每一種處方GLP-1注射都需要專用裝置，無論是自動注射筆、預填充式注射器或穿戴式貼片。這使得藥物需求與裝置需求之間幾乎呈現一對一的相關性，預計到2030年，全球接受GLP-1療法的患者總數將超過8,000萬人。這些療法用於治療第2型糖尿病、肥胖症以及日益成長的心血管代謝疾病，同時還有豐富的單株抗體和生物相似藥產品線在研發。每種裝置都必須兼顧劑量精準、易用性和符合檢驗，這就需要專門的裝置工程、填充和包裝，以及用於商業和臨床計畫的複合產品的法規合規性，但申辦公司很少具備這些能力。隨著自我給藥生物製藥療法擴展到更早的治療階段和新的適應症，對注射式藥物輸送裝置的需求將直接增加，為2034年之前的市場成長奠定基礎。

全球糖尿病和慢性疾病負擔日益加重。

隨著全球糖尿病和慢性疾病負擔的加重，對胰島素筆、自動注射器及其配套生產能力的需求也不斷增加。國際糖尿病聯盟（IDF）預測，到2030年，全球糖尿病患者人數將超過6.43億，而自體免疫疾病、心血管疾病和多發性硬化症的盛行率也將持續上升。注射給藥裝置在慢性疾病管理中發揮核心作用，既支持使用胰島素筆進行常規胰島素給藥，也支持使用自動注射器和穿戴式注射器進行標靶生物製藥治療。光是胰島素筆就佔了胰島素給藥裝置市場近一半的佔有率。隨著慢性疾病盛行率的上升以及用於劑量追蹤的連網型設備平台的普及，注射裝置的產量和複雜性也在不斷提高。這種持續的臨床需求將在整個預測期內直接轉化為對專業裝置設計、製造和品管服務需求的成長。

市場限制因素

儘管注射給藥裝置市場發展動力強勁，但仍面臨許多限制因素。與傳統的管瓶和注射器給藥方式相比，先進的自動注射器、穿戴式注射器和連網注射筆平台的高昂成本構成了一大障礙，尤其是在價格敏感且醫保償付受限的市場，這可能會減緩新興經濟體的普及速度。儘管人體工學方面取得了進步，但某些患者群體（包括兒童、老年人和視力或運動障礙患者）對針頭的恐懼、給藥錯誤以及裝置操作困難等問題仍然限制了自我給藥方式的普及。複合材料產品複雜且不斷變化的監管合規要求，涵蓋設計控制、可用性工程和藥物警戒等領域，延長了研發週期並推高了成本。同時，由於玻璃、聚合物和彈性體組件供應商集中在少數幾家公司，供應鏈較為脆弱，容易因供不應求而導致供應中斷。分散或新興市場通路中存在的假冒仿冒品和品管風險進一步擠壓了製造商的利潤空間，並威脅到病患安全。新型連網型設備穿戴裝置的償付率和普及率在不同地區仍有差異，患者和支付者對口服生物製劑和GLP-1替代療法的興趣日益濃厚，這在某些治療領域對注射劑構成了長期競爭威脅。成本、人為因素、監管、供應鏈以及產品劑型競爭等障礙，共同導致生物製藥行業成長速度放緩，儘管推動生物製藥擴張的基本因素依然強勁：慢性病負擔加重和居家照護的普及。

目錄

第1章 注射給藥裝置市場：簡介

  • 調查範圍
  • 市場區隔
  • 市場假設

第2章 注射給藥裝置市場：執行摘要

  • 市場概覽

第3章 注射給藥裝置市場：關鍵因素分析

  • 注射式藥物輸送裝置市場：市場促進因素
    • 擴大自我給藥生技藥品和GLP-1療法的應用
    • 全球糖尿病和慢性疾病負擔日益加重
    • 居家照護模式正逐步推廣。
    • 對設備製造能力的投資
  • 注射式藥物輸送裝置市場：限制與挑戰
    • 該設備高成本且償還受限。
    • 人為因素和零件供應限制
    • 監管和組合產品的複雜性
  • 注射式藥物輸送裝置市場：市場機會
    • 擴大互聯智慧注入器平台
    • 新興市場和穿戴式注射器的擴張

第4章 人工智慧、地緣政治、貿易與經濟趨勢

第5章 監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章 波特五力分析

第7章 注射給藥裝置市場：評估

  • 依產品類型
    • 自我注射器
    • 無針注射器
    • 自動注射器
    • 穿戴式注射器
    • 胰島素筆
  • 依藥物填充
    • 預填充設備
    • 可填充裝置
  • 依重複使用性
    • 可重複使用設備
    • 拋棄式設備
  • 依局部投藥
    • 肌肉內部
    • 皮內給藥
    • 皮下
  • 依最終用戶
    • 醫院
    • 專科診所
    • 居家醫療
  • 依地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第8章 注射給藥裝置市場：競爭格局

  • 市場集中度與結構
  • 競爭定位與市場佔有率分析（加值服務）

第9章 注射式藥物輸送裝置市場：新創企業資金籌措與投資趨勢

第10章 注射給藥裝置市場：公司概況與產品概況

  • Eli Lilly and Company
  • Biocon
  • BD
  • West Pharmaceutical Services, Inc
  • Johnson & Johnson Services, Inc.
  • Antares Pharma
  • AbbVie Inc.
  • Pfizer Inc.
  • Mylan NV
  • Vetter Pharma-Fertigung GmbH & Co.KG
    • 公司概況
    • 公司簡介
    • 財務概覽
    • 產品線
    • 策略舉措/熵

第11章 KOL的觀點

第12章 專案方法

第13章 關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0047

Injectable Drug Delivery Devices Market Summary

Overview:

  • The Injectable Drug Delivery Devices market is estimated at USD 44.20 billion in 2025 and is projected to reach USD 91.40 billion by 2034. Growth is anchored in the accelerating shift toward self-administered biologics and GLP-1 therapies, rapid expansion of home-based chronic disease management, and heavy manufacturing investment in prefillable syringes, autoinjectors, and connected pen platforms.
  • The global Injectable Drug Delivery Devices market is growing at a CAGR of 8.4% during the forecast period from 2026 to 2034.
  • By product type, the insulin pens segment dominated the Injectable Drug Delivery Devices market with a 41% share in 2025.
  • By drug loading, the pre-filled devices segment dominated the Injectable Drug Delivery Devices market with a 59% share in 2025.
  • By reusability, the disposable devices segment dominated the Injectable Drug Delivery Devices market with a 64% share in 2025.
  • By on-site delivery, the subcutaneous segment dominated the Injectable Drug Delivery Devices market with a 68% share in 2025.
  • By end-user, the home care settings segment dominated the Injectable Drug Delivery Devices market with a 45% share in 2025.
  • North America dominated the global Injectable Drug Delivery Devices market revenue with a 39% share in 2025, representing the highest regional market share globally.

An injectable drug delivery device is a medical device engineered to administer pharmaceutical and biologic products directly into the body through intramuscular, intradermal, or subcutaneous routes, spanning self-injectors, needle-free injectors, auto-injectors, wearable injectors, and insulin pens. Because a rapidly expanding pipeline of biologics, biosimilars, GLP-1 receptor agonists, and monoclonal antibodies requires precise, patient-friendly parenteral administration, pharmaceutical companies increasingly co-develop drug-device combination products with specialized device manufacturers and component suppliers rather than relying on conventional vial-and-syringe systems. These providers supply pre-filled and fillable device platforms, reusable and disposable formats, and integrated connectivity features that support dose accuracy, adherence tracking, and safe self-administration outside the clinical setting. The market is organized by product type across self-injectors, needle-free injectors, auto-injectors, wearable injectors, and insulin pens; by drug loading across pre-filled and fillable devices; by reusability across reusable and disposable devices; by on-site delivery across intramuscular, intradermal, and subcutaneous administration; and by end-user, led by home care settings alongside hospitals and specialty clinics. Driven by the rise of self-administered biologics and GLP-1 therapies, accelerating regulatory support for combination products, and sustained capital investment in prefillable syringe and autoinjector manufacturing capacity, injectable drug delivery devices have become essential infrastructure underpinning the shift of chronic-disease and specialty-biologic therapy from the clinic to the home.

Injectable Drug Delivery Devices Market Key Growth Drivers

  • The rapid clinical and commercial expansion of self-administered biologics and GLP-1 receptor agonist therapies is driving demand, with the installed base of active GLP-1 patients projected to exceed 80 million globally by 2030.
  • The rising global burden of diabetes is expanding demand for insulin pens and connected delivery systems, with the International Diabetes Federation projecting the number of people living with diabetes worldwide to reach over 643 million by 2030.
  • Pharmaceutical and biotechnology sponsors are increasingly shifting chronic-disease and specialty-biologic therapy toward home administration, expanding demand for user-optimized autoinjector, pen, and wearable injector platforms.
  • Accelerating regulatory support, including the FDA's updated combination-product guidance issued in 2024, is rewarding integrated device-drug co-development and increasing commercial device manufacturing demand.
  • Heavy capital investment in prefillable syringe and autoinjector manufacturing capacity, including BD's USD 110 million Nebraska expansion and Ypsomed's approximately CHF 500 million capacity build-out, is expanding device supply networks.
  • Stringent human-factors, combination-product, and quality-system requirements are concentrating demand among device manufacturers with proven regulatory track records and validated platforms.
  • The convergence of biologics growth, chronic disease burden, home-care adoption, and manufacturing investment is expected to sustain strong high-single-digit growth in the market through 2034.

Key Companies in Injectable Drug Delivery Devices Market

The competitive landscape is led by the following active manufacturers:

  • Eli Lilly and Company
  • Biocon
  • BD
  • West Pharmaceutical Services, Inc.
  • Johnson & Johnson Services, Inc.
  • Antares Pharma
  • AbbVie Inc.
  • Pfizer Inc.
  • Mylan N.V.
  • Vetter Pharma-Fertigung GmbH & Co.KG

Factors Contributing to the Growth of the Injectable Drug Delivery Devices Market

Market Drivers

Rapid Expansion of Self-Administered Biologics and GLP-1 Therapies

The most powerful driver of the Injectable Drug Delivery Devices market is the rapid clinical and commercial rise of self-administered biologics and GLP-1 receptor agonist therapies. Each injectable GLP-1 prescription requires a dedicated device, whether an auto-injector pen, prefilled syringe, or wearable patch, creating a near one-to-one correlation between drug demand and device demand, and the installed base of active GLP-1 patients is projected to exceed 80 million globally by 2030. These therapies treat type 2 diabetes, obesity, and a growing set of cardiometabolic conditions, and a deep pipeline of monoclonal antibodies and biosimilars is advancing alongside them. Because each device must combine dose accuracy, ease of use, and human-factors validation, commercial and clinical programs require specialized device engineering, fill-finish, and combination-product regulatory support that sponsors rarely possess in-house. As self-administered biologic therapy moves into earlier treatment lines and new indications, demand for injectable drug delivery device capacity expands directly, anchoring market growth through 2034.

Rising Global Burden of Diabetes and Chronic Disease

The growing global burden of diabetes and chronic disease is expanding demand for insulin pens, autoinjectors, and the manufacturing capacity that supports them. The International Diabetes Federation projects the number of people living with diabetes worldwide to reach over 643 million by 2030, while the prevalence of autoimmune disorders, cardiovascular disease, and multiple sclerosis continues to rise. Injectable drug delivery devices are central to chronic disease management, supporting both routine insulin administration through pens and targeted biologic treatment through autoinjectors and wearable injectors, and insulin pens alone account for close to half of the insulin delivery device market. As chronic disease prevalence increases and connected, dose-tracking device platforms gain adoption, the volume and sophistication of injectable device production rise in step. This sustained clinical demand translates directly into growing requirements for specialized device design, manufacturing, and quality services across the forecast period.

Market Restraints

Despite strong momentum, the Injectable Drug Delivery Devices market faces material constraints. The high cost of advanced autoinjector, wearable injector, and connected pen platforms relative to conventional vial-and-syringe administration is a significant barrier, particularly in price-sensitive and reimbursement-constrained markets, and can slow adoption in emerging economies. Needle-phobia, dosing errors, and device-handling difficulty among certain patient populations, including pediatric, elderly, and visually or motor-impaired users, constrain broader self-administration adoption despite ongoing human-factors improvements. Complex and evolving combination-product regulatory compliance across design controls, usability engineering, and pharmacovigilance lengthens development timelines and raises costs, while dependence on a concentrated base of glass, polymer, and elastomer component suppliers creates supply-chain fragility that shortages can disrupt. Counterfeit and quality-control risk in decentralized or emerging-market distribution channels further pressures manufacturer margins and patient safety. Reimbursement and adoption of newer connected and wearable device categories remain uneven across geographies, and growing patient and payer interest in oral biologic and GLP-1 alternatives poses a longer-term competitive threat to injectable formats in select therapeutic areas. Together, these cost, human-factors, regulatory, supply-chain, and competitive-format barriers temper the pace of growth, even as the underlying drivers of biologics expansion, chronic disease burden, and home-care adoption remain firmly intact.

Injectable Drug Delivery Devices Market Segment Analysis

The Injectable Drug Delivery Devices Market by Product Type (Self-Injectors, Needle-Free Injectors, Auto-Injectors, Wearable Injectors, Insulin Pens), Drug Loading (Pre-Filled Devices, Fillable Devices), Reusability (Reusable Devices, Disposable Devices), On-Site Delivery (Intramuscular, Intradermal, Subcutaneous), End-User (Hospitals, Specialty Clinics, Home Care Settings), and Geography (North America, Europe, Asia-Pacific, and Rest of World).

By Product Type

Dominant Subsegment: Insulin Pens.

The insulin pens segment accounted for 41% of the Injectable Drug Delivery Devices market in 2025. Insulin pens are the leading product type because they deliver a markedly more convenient and discreet alternative to the traditional vial-and-syringe system, combining pre-filled or replaceable cartridges with dose-memory and dosing-precision features that materially improve patient compliance across both type 1 and type 2 diabetes populations. The segment benefits from the sheer scale of the global diabetic population, extensive reimbursement coverage in developed markets, and growing adoption of connected smart pens that automatically track dosing and integrate with continuous glucose monitors. Established pharmaceutical leaders continue to expand pen-based insulin and biosimilar insulin portfolios across vial and prefilled-pen presentations, reinforcing the segment's breadth of use across hospitals, specialty clinics, and home care. While auto-injectors and wearable injectors are the fastest-growing categories, propelled by GLP-1 and biologic self-administration, the recurring, high-frequency nature of insulin pen use and its deep entrenchment in chronic diabetes management secure the segment's leadership across the forecast period.

By Drug Loading

Dominant Subsegment: Pre-Filled Devices.

The pre-filled devices segment accounted for 59% of the Injectable Drug Delivery Devices market in 2025. Pre-filled devices are the leading drug-loading format because they eliminate manual drawing and reconstitution steps, reduce dosing errors, and shorten time-to-injection, making them the preferred format for GLP-1 therapies, biologics, and vaccines administered outside clinical settings. Device manufacturers and component suppliers have concentrated recent capacity investment on integrated pre-filled syringe and cartridge systems that combine the barrel, plunger, and needle shield into a single verified platform, reducing regulatory and supply-chain complexity for sponsors. Pre-filled formats are especially critical for home-administered biologics and high-viscosity formulations that require validated, single-source device-drug combinations. Fillable devices retain an important role in hospital and specialty-clinic settings where flexible dosing across multiple products is required, but the scale of pre-filled adoption for self-administered chronic therapy secures the segment's leadership across the forecast period.

Injectable Drug Delivery Devices Market Region Analysis

Dominant Region: North America

North America accounted for 39% of the global Injectable Drug Delivery Devices market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a mature biologics and diabetes-care ecosystem, high GLP-1 and biosimilar adoption, strong reimbursement coverage, and clear FDA regulatory pathways for combination products, particularly in the United States. North America hosts the largest concentration of self-administered biologic and GLP-1 therapy programs and device manufacturing capacity, and sponsors benefit from proximity to leading device and component suppliers such as BD and West Pharmaceutical Services and to a dense network of fill-finish and assembly sites. The commercial scale of GLP-1 and biosimilar insulin therapies, combined with a deep biologics pipeline and rising home-care adoption, drives substantial device demand. Heavy investment is expanding capacity, including new prefillable syringe and autoinjector-component production, while major pharmaceutical companies are securing proprietary device platforms and domestic component supply. Strong reimbursement, regulatory clarity, and proximity to device and component supply anchor the region's continued leadership across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Injectable Drug Delivery Devices market, expanding at an estimated CAGR of approximately 10.1% across the forecast period. The region's elevated growth is driven by rising diabetes and chronic disease incidence, rapid expansion of biosimilar and GLP-1 uptake, and growing healthcare investment across China, Japan, India, South Korea, and Australia. China is scaling domestic prefillable syringe and pen manufacturing in alignment with its national biopharmaceutical development plans, Japan is advancing connected insulin pen adoption, India leverages large-scale, cost-competitive device and component manufacturing supported by government immunization programs, and South Korea and Australia benefit from expanding biosimilar and biologics manufacturing capacity. Government healthcare investment, expanding diabetic and biologic-eligible patient populations, and growing local device manufacturing capability are accelerating adoption, while regional manufacturers scale quality systems and align with global regulatory standards. The combination of high disease burden, infrastructure build-out, and local manufacturing investment positions Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 39% of the global Injectable Drug Delivery Devices market revenue in 2025. The United States dominates on the strength of its biologics and diabetes-care infrastructure, GLP-1 and biosimilar commercial scale, FDA regulatory clarity for combination products, and proximity to leading device and component suppliers, while heavy investment in prefillable syringe and autoinjector-component manufacturing capacity, and big-pharma moves to secure proprietary device platforms, reinforce its leadership.

Europe

Europe is a large and advanced regional market, supported by a strong medical-device engineering base, established EU Medical Device Regulation and EMA frameworks, and growing prefillable syringe and cartridge manufacturing capacity. Capacity investments such as Vetter Pharma-Fertigung's new Saarlouis facility and Ypsomed's expanded autoinjector production reinforce the region's role in supplying both diagnostic-adjacent and therapeutic self-injection device programs across Germany, France, the United Kingdom, Italy, and Spain.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by rising diabetes and chronic disease incidence, rapid biosimilar and GLP-1 uptake, and growing healthcare investment across China, Japan, India, South Korea, and Australia. China's domestic device manufacturing build-out, Japan's connected pen adoption, India's cost-competitive component manufacturing, and South Korea and Australia's expanding biologics capacity are accelerating regional device demand and local production activity.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding diabetes-care and biologics infrastructure, rising demand for self-injectable insulin and biosimilar therapies, and efforts to align regulatory frameworks with global quality standards are gradually broadening access, while international partnerships and technology transfer support the build-out of regional device assembly and fill-finish capacity.

Injectable Drug Delivery Devices Market Competitive Landscape

The Injectable Drug Delivery Devices market is classified as Moderately Fragmented. A group of large, integrated pharmaceutical and device manufacturers with proprietary platforms and global manufacturing reach, including Eli Lilly and Company, BD, and Johnson & Johnson Services, Inc., anchors the top tier, while specialized device and component suppliers such as West Pharmaceutical Services, Antares Pharma, and Vetter Pharma-Fertigung compete through platform engineering, human-factors expertise, and dedicated combination-product manufacturing capacity, increasing competition in the fastest-growing self-administration segments.

The competitive landscape can be evaluated across the following dimensions:

  • Market concentration: Moderately fragmented, with large integrated pharmaceutical and device players leading and a fast-growing field of specialized component and platform suppliers.
  • Leading players: Eli Lilly and Company, BD, Johnson & Johnson Services, Inc., and AbbVie Inc. anchor the top tier through proprietary device platforms and multi-site manufacturing networks.
  • Geographic reach: Leaders operate global, regionally distributed manufacturing and fill-finish networks essential for supplying prefillable syringes, autoinjectors, and pens across major end markets.
  • Service portfolio strength: Top players offer end-to-end device engineering, human-factors testing, GMP manufacturing, fill-finish, and connectivity integration.
  • Platform access: Ownership or secured supply of validated prefillable syringe, cartridge, and autoinjector platforms, including BD's Neopak glass prefillable syringe system and West's Synchrony platform, is a decisive advantage.
  • Strategic partnerships: Tie-ups between device manufacturers and pharmaceutical sponsors, such as the expanded Ypsomed-BD collaboration on large-volume prefillable syringe systems, extend platform reach.
  • M&A and investment activity: Active capacity expansion, including BD's USD 110 million Nebraska investment, Ypsomed's approximately CHF 500 million capacity build-out, and Vetter Pharma-Fertigung's new Saarlouis facility.
  • Manufacturing capabilities: High-speed assembly lines, validated glass and polymer component supply, and automated fill-finish systems are key competitive moats.
  • Innovation focus: Connected and smart injector platforms, large-volume wearable injectors, needle-free and microneedle delivery, and sustainable, low-waste device manufacturing.

Injectable Drug Delivery Devices Market Recent Developmental Activities

In June 2026, West Pharmaceutical Services, Inc., launched its West Synchrony prefillable syringe system across China and Southeast Asia, offering an integrated barrel, plunger, and needle-shield platform from a single supplier to support biologics and vaccine developers.

Strategic significance: Expands global availability of a fully verified prefillable syringe platform and strengthens West's position in high-growth Asia-Pacific biologics manufacturing.

In May 2026, Vetter Pharma-Fertigung GmbH & Co.KG began construction of a new injectable-medicines manufacturing site in Saarlouis, Germany, representing an investment of almost EUR 500 million with cleanrooms dedicated to filling pre-sterilised syringes and vials for complex injectable medicines.

Strategic significance: Expands European aseptic fill-finish capacity for complex injectable and combination-product programs.

Injectable Drug Delivery Devices Market Segmentation

Injectable Drug Delivery Devices Market by Product Type

  • Self-Injectors
  • Needle-Free Injectors
  • Auto-Injectors
  • Wearable Injectors
  • Insulin Pens

Injectable Drug Delivery Devices Market by Drug Loading

  • Pre-Filled Devices
  • Fillable Devices

Injectable Drug Delivery Devices Market by Reusability

  • Reusable Devices
  • Disposable Devices

Injectable Drug Delivery Devices Market by On-Site Delivery

  • Intramuscular
  • Intradermal
  • Subcutaneous

Injectable Drug Delivery Devices Market by End-User

  • Hospitals
  • Specialty Clinics
  • Home Care Settings

Injectable Drug Delivery Devices Market by Geography

  • North America Injectable Drug Delivery Devices Market
  • United States Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
  • Canada Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
  • Mexico Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
  • Europe Injectable Drug Delivery Devices Market
  • Germany Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
  • United Kingdom Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
  • France Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
  • Italy Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
  • Spain Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
  • Rest of Europe Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
  • Asia-Pacific Injectable Drug Delivery Devices Market
  • China Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
  • Japan Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
  • India Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
  • Australia Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
  • South Korea Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
  • Rest of Asia-Pacific Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
  • Rest of the World (RoW) Injectable Drug Delivery Devices Market
  • Middle East Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
  • Africa Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
  • South America Injectable Drug Delivery Devices Market Size in USD million (2023-2034)

Key Takeaways from the Injectable Drug Delivery Devices Market Report Study

  • Market size analysis for the current Injectable Drug Delivery Devices market size (2025), and market forecast for 9 years (2026 to 2034).
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
  • Key companies dominating the global Injectable Drug Delivery Devices market.
  • Various opportunities available for competitors in the Injectable Drug Delivery Devices market space.
  • What are the top-performing segments in 2025? How will these segments perform in 2034?
  • Which are the top-performing regions and countries in the current Injectable Drug Delivery Devices market scenario?
  • Which are the regions and countries where companies should concentrate their opportunities for Injectable Drug Delivery Devices market growth in the future?

Target audience who can benefit from this Injectable Drug Delivery Devices market report study

  • Injectable Drug Delivery Devices product providers
  • Research organizations and consulting companies
  • Neurodegenerative disease therapeutics-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in Injectable Drug Delivery Devices
  • Various end-users who want to know more about the Injectable Drug Delivery Devices market and the latest technological developments in the Injectable Drug Delivery Devices market.

Frequently Asked Questions:

Q1. What is the growth rate of the Injectable Drug Delivery Devices market?

The Injectable Drug Delivery Devices market is projected to expand at a CAGR of 8.4% during the forecast period from 2026-2034.

Q2. What is the market size of the Injectable Drug Delivery Devices market?

The Injectable Drug Delivery Devices market is estimated at USD 44.20 billion in 2025 and is projected to reach USD 91.40 billion by 2034.

Q3. Which region dominates the Injectable Drug Delivery Devices market?

North America dominated the Injectable Drug Delivery Devices market with a 39% share of global revenue in 2025, supported by a mature biologics and diabetes-care ecosystem, strong reimbursement coverage, FDA regulatory clarity for combination products, and the largest concentration of self-administered biologic and GLP-1 therapy programs and manufacturing capacity. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Injectable Drug Delivery Devices market?

The principal drivers are the rapid clinical and commercial expansion of self-administered biologics and GLP-1 therapies, with the installed base of active GLP-1 patients projected to exceed 80 million globally by 2030; the rising global burden of diabetes, with the International Diabetes Federation projecting cases to reach over 643 million by 2030; increasing shift toward home-based and patient-centric care; accelerating regulatory support for combination products; and heavy investment in prefillable syringe and autoinjector manufacturing capacity.

Q5. Who are the major players in the Injectable Drug Delivery Devices market?

The major players include Eli Lilly and Company, Biocon, BD, West Pharmaceutical Services, Inc., Johnson & Johnson Services, Inc., Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., and Vetter Pharma-Fertigung GmbH & Co.KG, among other active providers profiled in the Competitive Landscape section. Eli Lilly and Company, BD, Johnson & Johnson Services, Inc., and AbbVie Inc. lead through proprietary device platforms and multi-site manufacturing reach.

Table of Contents

1. Injectable Drug Delivery Devices Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumptions

2. Injectable Drug Delivery Devices Market Executive Summary

  • 2.1 Market at a Glance

3. Injectable Drug Delivery Devices Market Key Factors Analysis

  • 3.1 Injectable Drug Delivery Devices Market Drivers
    • 3.1.1 Expansion of Self-Administered Biologics and GLP-1 Therapies
    • 3.1.2 Rising Global Burden of Diabetes and Chronic Disease
    • 3.1.3 Increasing Shift Toward Home-Based Care
    • 3.1.4 Investment in Device Manufacturing Capacity
  • 3.2 Injectable Drug Delivery Devices Market Restraints and Challenges
    • 3.2.1 High Device Cost and Reimbursement Constraints
    • 3.2.2 Human-Factors and Component Supply Constraints
    • 3.2.3 Regulatory and Combination-Product Complexity
  • 3.3 Injectable Drug Delivery Devices Market Opportunities
    • 3.3.1 Connected and Smart Injector Platform Scale-Up
    • 3.3.2 Emerging-Market and Wearable Injector Expansion

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

  • 5.1 United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Injectable Drug Delivery Devices Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Buyers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Injectable Drug Delivery Devices Market Assessment

  • 7.1 By Product Type
    • 7.1.1 Self-Injectors
    • 7.1.2 Needle-Free Injectors
    • 7.1.3 Auto-Injectors
    • 7.1.4 Wearable Injectors
    • 7.1.5 Insulin Pens
  • 7.2 By Drug Loading
    • 7.2.1 Pre-Filled Devices
    • 7.2.2 Fillable Devices
  • 7.3 By Reusability
    • 7.3.1 Reusable Devices
    • 7.3.2 Disposable Devices
  • 7.4 By On-Site Delivery
    • 7.4.1 Intramuscular
    • 7.4.2 Intradermal
    • 7.4.3 Subcutaneous
  • 7.5 By End-User
    • 7.5.1 Hospitals
    • 7.5.2 Specialty Clinics
    • 7.5.3 Home Care Settings
  • 7.6 By Geography
    • 7.6.1 North America
      • 7.6.1.1 United States Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
      • 7.6.1.2 Canada Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
      • 7.6.1.3 Mexico Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
    • 7.6.2 Europe
      • 7.6.2.1 Germany Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
      • 7.6.2.2 United Kingdom Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
      • 7.6.2.3 France Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
      • 7.6.2.4 Italy Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
      • 7.6.2.5 Spain Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
      • 7.6.2.6 Rest of Europe Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
    • 7.6.3 Asia-Pacific
      • 7.6.3.1 China Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
      • 7.6.3.2 Japan Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
      • 7.6.3.3 India Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
      • 7.6.3.4 Australia Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
      • 7.6.3.5 South Korea Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
      • 7.6.3.6 Rest of Asia-Pacific Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
    • 7.6.4 Rest of World
      • 7.6.4.1 Middle East Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
      • 7.6.4.2 Africa Injectable Drug Delivery Devices Market Size in USD million (2023-2034)
      • 7.6.4.3 South America Injectable Drug Delivery Devices Market Size in USD million (2023-2034)

8. Injectable Drug Delivery Devices Market Competitive Landscape

  • 8.1 Market Concentration and Structure
  • 8.2 Competitive Positioning and Market Share Analysis (Premium Offering)

9. Injectable Drug Delivery Devices Market Startup Funding and Investment Trends

10. Injectable Drug Delivery Devices Market Company and Product Profiles

  • 10.1 Eli Lilly and Company
    • 10.1.1 Company Overview
    • 10.1.2 Company Snapshot
    • 10.1.3 Financial Overview
    • 10.1.4 Service Portfolio
    • 10.1.5 Strategic Initiatives / Entropy
  • 10.2 Biocon
    • 10.2.1 Company Overview
    • 10.2.2 Company Snapshot
    • 10.2.3 Financial Overview
    • 10.2.4 Product Portfolio
    • 10.2.5 Strategic Initiatives / Entropy
  • 10.3 BD
    • 10.3.1 Company Overview
    • 10.3.2 Company Snapshot
    • 10.3.3 Financial Overview
    • 10.3.4 Product Portfolio
    • 10.3.5 Strategic Initiatives / Entropy
  • 10.4 West Pharmaceutical Services, Inc
    • 10.4.1 Company Overview
    • 10.4.2 Company Snapshot
    • 10.4.3 Financial Overview
    • 10.4.4 Product Portfolio
    • 10.4.5 Strategic Initiatives / Entropy
  • 10.5 Johnson & Johnson Services, Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Company Snapshot
    • 10.5.3 Financial Overview
    • 10.5.4 Product Portfolio
    • 10.5.5 Strategic Initiatives / Entropy
  • 10.6 Antares Pharma
    • 10.6.1 Company Overview
    • 10.6.2 Company Snapshot
    • 10.6.3 Financial Overview
    • 10.6.4 Product Portfolio
    • 10.6.5 Strategic Initiatives / Entropy
  • 10.7 AbbVie Inc.
    • 10.7.1 Company Overview
    • 10.7.2 Company Snapshot
    • 10.7.3 Financial Overview
    • 10.7.4 Product Portfolio
    • 10.7.5 Strategic Initiatives / Entropy
  • 10.8 Pfizer Inc.
    • 10.8.1 Company Overview
    • 10.8.2 Company Snapshot
    • 10.8.3 Financial Overview
    • 10.8.4 Product Portfolio
    • 10.8.5 Strategic Initiatives / Entropy
  • 10.9 Mylan N.V.
    • 10.9.1 Company Overview
    • 10.9.2 Company Snapshot
    • 10.9.3 Financial Overview
    • 10.9.4 Product Portfolio
    • 10.9.5 Strategic Initiatives / Entropy

10. Vetter Pharma-Fertigung GmbH & Co.KG

    • 10.10.1 Company Overview
    • 10.10.2 Company Snapshot
    • 10.10.3 Financial Overview
    • 10.10.4 Product Portfolio
    • 10.10.5 Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us

List of Tables

  • Table 1: Injectable Drug Delivery Devices Market in Global (2023-2034)
  • Table 2: Injectable Drug Delivery Devices Market in Global by Product Type (2023-2034)
  • Table 3: Injectable Drug Delivery Devices Market in Global by Drug Loading (2023-2034)
  • Table 4: Injectable Drug Delivery Devices Market in Global by Reusability (2023-2034)
  • Table 5: Injectable Drug Delivery Devices Market in Global by On-Site Delivery (2023-2034)
  • Table 6: Injectable Drug Delivery Devices Market in Global by End-User (2023-2034)
  • Table 7: Injectable Drug Delivery Devices Market in Global by Geography (2023-2034)
  • Table 8: Injectable Drug Delivery Devices Market in North America (2023-2034)
  • Table 9: Injectable Drug Delivery Devices Market in the United States (2023-2034)
  • Table 10: Injectable Drug Delivery Devices Market in Canada (2023-2034)
  • Table 11: Injectable Drug Delivery Devices Market in Mexico (2023-2034)
  • Table 12: Injectable Drug Delivery Devices Market in Europe (2023-2034)
  • Table 13: Injectable Drug Delivery Devices Market in Germany (2023-2034)
  • Table 14: Injectable Drug Delivery Devices Market in United Kingdom (2023-2034)
  • Table 15: Injectable Drug Delivery Devices Market in France (2023-2034)
  • Table 16: Injectable Drug Delivery Devices Market in Italy (2023-2034)
  • Table 17: Injectable Drug Delivery Devices Market in Spain (2023-2034)
  • Table 18: Injectable Drug Delivery Devices Market in the Rest of Europe (2023-2034)
  • Table 19: Injectable Drug Delivery Devices Market in Asia-Pacific (2023-2034)
  • Table 20: Injectable Drug Delivery Devices Market in China (2023-2034)
  • Table 21: Injectable Drug Delivery Devices Market in Japan (2023-2034)
  • Table 22: Injectable Drug Delivery Devices Market in India (2023-2034)
  • Table 23: Injectable Drug Delivery Devices Market in Australia (2023-2034)
  • Table 24: Injectable Drug Delivery Devices Market in South Korea (2023-2034)
  • Table 25: Injectable Drug Delivery Devices Market in Rest of Asia-Pacific (2023-2034)
  • Table 26: Injectable Drug Delivery Devices Market in the Rest of the World (2023-2034)
  • Table 27: Injectable Drug Delivery Devices Market in the Middle East (2023-2034)
  • Table 28: Injectable Drug Delivery Devices Market in Africa (2023-2034)
  • Table 29: Injectable Drug Delivery Devices Market in South America (2023-2034)
  • Table 30: Competitive Landscape
  • Table 31: Startup Funding and Investment Trends

List of Figures

  • Figure 1: Injectable Drug Delivery Devices Market Drivers
  • Figure 2: Injectable Drug Delivery Devices Market Restraints
  • Figure 3: Injectable Drug Delivery Devices Market Opportunities
  • Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
  • Figure 5: Regulatory Analysis (US, EU, Japan, China)
  • Figure 6: Porter's Five Forces Analysis
  • Figure 7: Competitive Analysis
  • Figure 8: Injectable Drug Delivery Devices Market in Global (2023-2034)
  • Figure 9: Injectable Drug Delivery Devices Market in Global by Product Type (2023-2034)
  • Figure 10: Injectable Drug Delivery Devices Market in Global by Drug Loading (2023-2034)
  • Figure 11: Injectable Drug Delivery Devices Market in Global by Reusability (2023-2034)
  • Figure 12: Injectable Drug Delivery Devices Market in Global by On-Site Delivery (2023-2034)
  • Figure 13: Injectable Drug Delivery Devices Market in Global by End-User (2023-2034)
  • Figure 14: Injectable Drug Delivery Devices Market in Global by Geography (2023-2034)
  • Figure 15: Injectable Drug Delivery Devices Market in North America (2023-2034)
  • Figure 16: Injectable Drug Delivery Devices Market in the United States (2023-2034)
  • Figure 17: Injectable Drug Delivery Devices Market in Canada (2023-2034)
  • Figure 18: Injectable Drug Delivery Devices Market in Mexico (2023-2034)
  • Figure 19: Injectable Drug Delivery Devices Market in Europe (2023-2034)
  • Figure 20: Injectable Drug Delivery Devices Market in Germany (2023-2034)
  • Figure 21: Injectable Drug Delivery Devices Market in United Kingdom (2023-2034)
  • Figure 22: Injectable Drug Delivery Devices Market in France (2023-2034)
  • Figure 23: Injectable Drug Delivery Devices Market in Italy (2023-2034)
  • Figure 24: Injectable Drug Delivery Devices Market in Spain (2023-2034)
  • Figure 25: Injectable Drug Delivery Devices Market in the Rest of Europe (2023-2034)
  • Figure 26: Injectable Drug Delivery Devices Market in Asia-Pacific (2023-2034)
  • Figure 27: Injectable Drug Delivery Devices Market in China (2023-2034)
  • Figure 28: Injectable Drug Delivery Devices Market in Japan (2023-2034)
  • Figure 29: Injectable Drug Delivery Devices Market in India (2023-2034)
  • Figure 30: Injectable Drug Delivery Devices Market in Australia (2023-2034)
  • Figure 31: Injectable Drug Delivery Devices Market in South Korea (2023-2034)
  • Figure 32: Injectable Drug Delivery Devices Market in Rest of Asia-Pacific (2023-2034)
  • Figure 33: Injectable Drug Delivery Devices Market in the Rest of the World (2023-2034)
  • Figure 34: Injectable Drug Delivery Devices Market in the Middle East (2023-2034)
  • Figure 35: Injectable Drug Delivery Devices Market in Africa (2023-2034)
  • Figure 36: Injectable Drug Delivery Devices Market in South America (2023-2034)
  • Figure 37: Competitive Landscape
  • Figure 38: Startup Funding and Investment Trends